Amanda Ebbutt, partner, and Paul England, senior counsel – knowledge at Taylor Wessing.

10 June 2025FeaturesEuropeAmanda Ebbutt & Paul England

Three reasons why the UK should reconsider joining the UPC

Two years since the UPC opened its doors, various developments might influence the UK government to reassess its position, write Amanda Ebbutt and Paul England of Taylor Wessing.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UK court clears the way for Amgen and Samsung to launch biosimilars

22 May 2025 AstraZeneca subsidiary Alexion suffers setback in bid to stop rivals launching biosimilars of blood disorder drug | Ruling concerns an error in original patent application | Decision follows UPC defeat for Alexion over eculizumab patent.

Europe

UPC issues first decision on second medical use

13 May 2025 Court of First Instance rules on Sanofi v Amgen antibodies dispute | Claims dismissed as “unfounded” and lacking in evidence | All parties ordered to pay costs totalling €45m ($50m).

Europe

UPC orders 17-country ban on EOFlow's pumps in Insulet feud

2 May 2025 Appeals court overturns lower court ruling in decision establishing key standards for patent interpretation | Global dispute between the two insulin pump makers intensifies amid separate US trade secret litigation.